Dermata Therapeutics Q1 2024 net loss $3.1M; cash runway into Q3 2024

Dermata Therapeutics, Inc.

2025-Q1 EPS reported -$7.06

Cash and equivalents $4.7M as of March 31, 2024, down from $7.4M at Dec 31, 2023.
Net loss of $3.1M for Q1 2024; R&D expenses rose to $1.6M on STAR-1 trial costs.
STAR-1 Phase 3 acne trial enrollment on track for completion by end of 2024; topline data expected Q1 2025.
Partnership discussions ongoing for DMT410 topical botulinum toxin; Japanese patent issued for hyperhidrosis.
Company expects current cash to fund operations only into Q3 2024.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Dermata Therapeutics, Inc. reported first quarter ended March 31, 2024 results: net income $3.1 million of net loss.

Period: first quarter ended March 31, 2024
Net income: $3.1 million of net loss
Result: reported results

Exact text from the filing

The decrease in cash and cash equivalents resulted from $3.1 million of net loss for the quarter ended March 31, 2024, and $0.2 million of decreased accrued liabilities, offset by $0.6 million in stock-based compensation expense.

View on SEC.gov

1047 earnings releases filed in the last 30 days. Browse all earnings releases →

Dermata Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001654954-24-006396

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.